{"id":55612,"date":"2024-02-07T05:32:57","date_gmt":"2024-02-07T05:32:57","guid":{"rendered":"https:\/\/medsname.com\/lipvas\/"},"modified":"2026-05-01T10:49:12","modified_gmt":"2026-05-01T10:49:12","slug":"lipvas","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/lipvas\/","title":{"rendered":"Thyronorm"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">&#9889; Quick Answer &mdash; What is Lipvas?<\/h3>\n<p style=\"margin:0;\"><strong>Thyronorm<\/strong> je <strong>10 \/ 20 \/ 40 mg atorvastatin tablet<\/strong> from Cipla &mdash; a high-intensity HMG-CoA reductase inhibitor (statin), lipophilic. Statins reduce cardiovascular events by <strong>20-30% per mmol\/L LDL-cholesterol reduction<\/strong> across primary prevention, secondary prevention, diabetes, and post-stroke populations. Atorvastatin was introduced by Parke-Davis\/Pfizer in 1996 as <strong>Lipitor<\/strong> &mdash; the best-selling drug of all time at its peak ($12.5 billion\/year in 2006). Lipophilic statin, hepatically cleared via CYP3A4. Dose range 10-80 mg once daily; 40-80 mg are high-intensity by AHA\/ACC 2018 lipid guidelines. Potency: atorvastatin 40 mg typically reduces LDL-C by 50%; 80 mg by 55%. Typical dose: once daily, evening (for short-half-life statins) or any time for atorvastatin (half-life long enough that timing does not matter). Main side effects: muscle symptoms (0.1-1% with confirmed CK elevation; up to 10% nocebo muscle aches), mild transaminase elevation (3%), new-onset diabetes in at-risk patients (~0.2 per 100 patient-years). Absolutely contraindicated in pregnancy, active liver disease, rhabdomyolysis history.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Co z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch <a href=\"https:\/\/medsbase.com\/cs\/reviews\/\">recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\"><strong>Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n<h3>Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n<p>Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n<h2 class=\"wp-block-heading\">What Is Lipvas?<\/h2>\n<p>Lipvas is an oral 10 \/ 20 \/ 40 mg atorvastatin tablet from Cipla, supplied in 30-180 tablets. Atorvastatin was introduced by Parke-Davis\/Pfizer in 1996 as <strong>Lipitor<\/strong> &mdash; the best-selling drug of all time at its peak ($12.5 billion\/year in 2006). Lipophilic statin, hepatically cleared via CYP3A4. Dose range 10-80 mg once daily; 40-80 mg are high-intensity by AHA\/ACC 2018 lipid guidelines.<\/p>\n<h2 class=\"wp-block-heading\">How Atorvastatin Works<\/h2>\n<p>Atorvastatin inhibits <strong>HMG-CoA redukt\u00e1zy<\/strong>, the rate-limiting enzyme of hepatic cholesterol biosynthesis. Downstream:<\/p>\n<ul>\n<li><strong>Reduced intracellular cholesterol in hepatocytes<\/strong> &mdash; triggers sterol-regulatory element binding protein (SREBP) activation and upregulation of LDL-receptor expression on the hepatocyte surface<\/li>\n<li><strong>Increased clearance of circulating LDL-C<\/strong> &mdash; the primary LDL-lowering mechanism<\/li>\n<li><strong>Modest triglyceride reduction<\/strong> (10-20%) and modest HDL rise (5-10%)<\/li>\n<li><strong>Pleiotropic effects<\/strong> beyond LDL-lowering &mdash; reduced vascular inflammation (hs-CRP drop), improved endothelial function, plaque stabilisation, reduced platelet reactivity. The magnitude of the clinical benefit across trials exceeds what is explained by LDL-C change alone.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Lipvas Dosage<\/h2>\n<p><strong>Primary prevention (no prior CV event):<\/strong> start 10-20 mg once daily; titrate to target based on 10-year ASCVD risk. For diabetics or ASCVD risk &gt;7.5%, moderate-intensity (20-40 mg) is typical.<\/p>\n<p><strong>Secondary prevention (prior MI, stroke, PAD, or diabetic CVD):<\/strong> high-intensity therapy &mdash; 40-80 mg once daily. Target LDL-C &lt;1.8 mmol\/L (&lt;70 mg\/dL) per 2019 ESC and &lt;1.4 mmol\/L (&lt;55 mg\/dL) for very-high-risk ASCVD per 2021 ESC update.<\/p>\n<p><strong>Familial hypercholesterolaemia:<\/strong> maximum-tolerated statin (usually 80 mg) often combined with ezetimibe 10 mg and\/or PCSK9 inhibitor (alirocumab\/evolocumab\/inclisiran) to achieve guideline targets.<\/p>\n<p><strong>Pod\u00e1v\u00e1n\u00ed:<\/strong> once daily with or without food. Evening dosing is no longer required for atorvastatin (long half-life); any consistent time of day is fine.<\/p>\n<p><strong>Monitorov\u00e1n\u00ed:<\/strong><\/p>\n<ul>\n<li><strong>Vstupn\u00ed vy\u0161et\u0159en\u00ed:<\/strong> full lipid panel, LFTs (ALT), creatine kinase (CK), HbA1c or fasting glucose, creatinine, thyroid-stimulating hormone (TSH) if not recently checked.<\/li>\n<li><strong>4-12 t\u00fddn\u016f:<\/strong> repeat lipids to assess response. Expect atorvastatin 40 mg typically reduces LDL-C by 50%; 80 mg by 55%. Dose-escalate if target not met.<\/li>\n<li><strong>Ro\u010dn\u011b:<\/strong> lipids, LFTs (unless symptomatic). CK only on muscle complaints, not routinely.<\/li>\n<li><strong>P\u0159eru\u0161te a vy\u0161et\u0159ete:<\/strong> CK &gt;10&times; ULN, ALT &gt;3&times; ULN and rising, persistent unexplained muscle pain with CK &gt;5&times; ULN, rhabdomyolysis (dark urine, profound weakness).<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Evidence for Atorvastatin<\/h2>\n<p><strong>CARDS (2004)<\/strong> &mdash; atorvastatin 10 mg in 2,838 type 2 diabetics without overt CVD reduced major CV events by 37% (primary prevention in diabetes). <strong>ASCOT-LLA (2003)<\/strong> &mdash; atorvastatin 10 mg in 10,305 hypertensives reduced CV events by 36%. <strong>TNT (2005)<\/strong> &mdash; 80 mg vs 10 mg in stable CAD; high-dose reduced events by 22%. <strong>PROVE-IT (2004)<\/strong> &mdash; atorvastatin 80 mg vs pravastatin 40 mg post-ACS; atorvastatin superior. <strong>SPARCL (2006)<\/strong> &mdash; atorvastatin 80 mg after stroke\/TIA reduced recurrent stroke by 16%.<\/p>\n<h2 class=\"wp-block-heading\">Schv\u00e1len\u00e9 a v\u011bdecky podlo\u017een\u00e9 indikace<\/h2>\n<ul>\n<li>Primary and secondary prevention of cardiovascular disease in patients with dyslipidaemia<\/li>\n<li>Type 2 diabetes (CARDS) even with &#8220;normal&#8221; LDL<\/li>\n<li>Post-stroke secondary prevention (SPARCL)<\/li>\n<li>Familial hypercholesterolaemia (80 mg; often requires combination with ezetimibe or PCSK9 inhibitor)<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Practical Considerations<\/h2>\n<p><strong>Grapefruit juice interacts<\/strong> &mdash; inhibits intestinal CYP3A4, raising atorvastatin levels 2-3 fold. Small amounts (one glass, once) usually OK; regular daily grapefruit should be avoided. <strong>Siln\u00e9 inhibitory CYP3A4<\/strong> (clarithromycin, ritonavir, ketoconazole) substantially raise atorvastatin levels and myopathy risk.<\/p>\n<h2 class=\"wp-block-heading\">Vedlej\u0161\u00ed \u00fa\u010dinky<\/h2>\n<p><strong>\u010cast\u00e9 (&gt;1 %):<\/strong><\/p>\n<ul>\n<li><strong>Myalgia (muscle pain)<\/strong> &mdash; bothersome in 5-10% of users; confirmed statin-associated muscle symptoms with CK rise in 0.1-1%. High nocebo component: SAMSON trial (2020) showed no difference between statin and placebo in double-blind n-of-1 crossovers in many &#8220;statin-intolerant&#8221; patients.<\/li>\n<li><strong>M\u00edrn\u00e9 zv\u00fd\u0161en\u00ed transamin\u00e1z<\/strong> &mdash; 3% have ALT rise below 3&times; ULN; usually transient and does not require dose change.<\/li>\n<li><strong>New-onset diabetes<\/strong> &mdash; absolute excess ~0.2 per 100 patient-years, mostly in prediabetic patients. CV benefit far exceeds diabetes risk.<\/li>\n<li><strong>Headache, dyspepsia, nausea<\/strong><\/li>\n<li><strong>Erektiln\u00ed dysfunkce<\/strong> (uncommon; mechanism unclear)<\/li>\n<li><strong>Sleep disturbance, cognitive fog<\/strong> (reported but not consistent in RCTs)<\/li>\n<\/ul>\n<p><strong>Nep\u0159\u00edli\u0161 \u010dast\u00e9, ale klinicky v\u00fdznamn\u00e9:<\/strong><\/p>\n<ul>\n<li><strong>Rabdomyol\u00fdza<\/strong> (&lt;1 per 10,000 patient-years) &mdash; severe muscle breakdown, renal failure risk. Stop immediately on dark urine + profound weakness + CK &gt;10&times; ULN.<\/li>\n<li><strong>Imunitn\u011b zprost\u0159edkovan\u00e1 nekrotizuj\u00edc\u00ed myopatie<\/strong> &mdash; rare persistent myopathy that continues after stopping statin; anti-HMGCR antibody mediated. Needs immunosuppressive treatment.<\/li>\n<li><strong>Severe transaminitis \/ drug-induced liver injury<\/strong> &mdash; rare; stop if ALT &gt;3&times; ULN with symptoms or rising trajectory.<\/li>\n<li><strong>Perifern\u00ed neuropatie<\/strong> (vz\u00e1cn\u00e9)<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Kontraindikace<\/h2>\n<ul>\n<li><strong>T\u011bhotenstv\u00ed a kojen\u00ed<\/strong> &mdash; statins are contraindicated; cholesterol is required for fetal neurodevelopment.<\/li>\n<li><strong>Aktivn\u00ed jatern\u00ed onemocn\u011bn\u00ed<\/strong> or unexplained persistent ALT &gt;3&times; ULN.<\/li>\n<li><strong>Prior rhabdomyolysis or severe statin-intolerance<\/strong> confirmed in double-blind rechallenge.<\/li>\n<li><strong>Sou\u010dasn\u00e9 u\u017e\u00edv\u00e1n\u00ed siln\u00fdch inhibitor\u016f CYP3A4<\/strong> (for atorvastatin): clarithromycin, itraconazole, ritonavir &mdash; hold statin or switch to rosuvastatin\/pravastatin.<\/li>\n<li>Hypersensitivity to the statin.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Interakce s l\u00e9\u010divy<\/h2>\n<ul>\n<li><strong>Siln\u00e9 inhibitory CYP3A4 \u2014 KRITICK\u00c9.<\/strong> Clarithromycin, erythromycin, itraconazole, ketoconazole, ritonavir, cobicistat, ciclosporin &mdash; raise atorvastatin levels 2-10 fold. Hold statin during short antibiotic courses; switch to rosuvastatin or pravastatin for long-term CYP3A4 inhibitor co-therapy.<\/li>\n<li><strong>Grapefruitov\u00e1 \u0161\u0165\u00e1va<\/strong> &mdash; avoid regular daily consumption with atorvastatin (2-3 fold interaction).<\/li>\n<li><strong>Fibrates (gemfibrozil, fenofibrate)<\/strong> &mdash; additive myopathy risk. Gemfibrozil is the worst; fenofibrate is the preferred fibrate for combination. Reserve combinations for specialist dyslipidaemia care.<\/li>\n<li><strong>Niacin high-dose<\/strong> &mdash; additive myopathy risk. Low-dose niacin (1-2 g) usually tolerated.<\/li>\n<li><strong>Warfarin<\/strong> &mdash; small INR rise with statin initiation; check INR 1 week after starting. Not a contraindication.<\/li>\n<li><strong>Digoxin<\/strong> &mdash; small digoxin level rise with atorvastatin (P-glycoprotein); usually not clinically significant.<\/li>\n<li><strong>Alkohol<\/strong> &mdash; heavy intake raises liver injury risk. Moderate intake is acceptable.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Skladov\u00e1n\u00ed<\/h2>\n<p>Store Lipvas below 25&deg;C in the original blister pack. Keep out of reach of children.<\/p>\n<h2 id=\"faqs\">\u010casto kladen\u00e9 dotazy<\/h2>\n<h3 class=\"wp-block-heading\">Do I have to take Lipvas at night?<\/h3>\n<p>No &mdash; atorvastatin has a 20-30-hour half-life, long enough that the ~24-hour cycle of nocturnal cholesterol synthesis is covered regardless of dose timing. Morning dosing with other medications is fine. The &#8220;take statins at night&#8221; rule comes from short-half-life statins (simvastatin, lovastatin).<\/p>\n<h3 class=\"wp-block-heading\">What if I get muscle aches on Lipvas?<\/h3>\n<p>Common and rarely dangerous. Check creatine kinase (CK). If CK is normal, the pains are usually not statin-related &mdash; the SAMSON trial (2020) showed most &#8220;statin-intolerant&#8221; patients had equal aches on placebo in double-blind crossover. Options: continue statin with vitamin D supplementation (if deficient), try coenzyme Q10 (weak evidence but low-risk), switch statin (rosuvastatin has lower muscle-symptom rate than simvastatin and atorvastatin in some trials), lower the dose, or adopt alternate-day dosing. Only stop if CK &gt;10&times; ULN, symptoms are disabling, or there is objective weakness.<\/p>\n<h3 class=\"wp-block-heading\">Will Lipvas give me diabetes?<\/h3>\n<p>Statins cause a small excess of new-onset diabetes &mdash; approximately 1 extra diabetes case per 1,000 people per year, mostly in those already at high diabetes risk (overweight, prediabetes, family history). The same treatment prevents roughly 5-10 cardiovascular events per 1,000 people per year in the same populations &mdash; so the net benefit is strongly positive. Do not stop a statin because of diabetes risk alone.<\/p>\n<h3 class=\"wp-block-heading\">Can I take Lipvas with grapefruit juice?<\/h3>\n<p>Occasional small amounts of grapefruit juice (one glass) are usually fine. Daily consumption substantially raises atorvastatin levels (2-3 fold via intestinal CYP3A4 inhibition) and increases myopathy risk. If you drink grapefruit juice regularly, switch to rosuvastatin or pravastatin, which have minimal grapefruit interaction.<\/p>\n<h3 class=\"wp-block-heading\">How long will I need to take Lipvas?<\/h3>\n<p>Indefinitely, in almost all cases. Stopping a statin causes LDL-C to rebound within weeks and cardiovascular protection is lost within months. Statins are lifelong preventive therapy for atherosclerotic disease, not a short course.<\/p>\n<h3 class=\"wp-block-heading\">Can I take Lipvas in pregnancy?<\/h3>\n<p>No &mdash; statins are contraindicated in pregnancy and breastfeeding. Cholesterol is required for fetal neurodevelopment; statins cross the placenta. Stop the statin before planned pregnancy; if pregnancy is unplanned, stop immediately and discuss risks with a specialist. Familial hypercholesterolaemia patients can usually safely defer statin therapy during pregnancy and breastfeeding.<\/p>\n<h3 class=\"wp-block-heading\">Where can I buy Lipvas online?<\/h3>\n<p>You can buy Lipvas (atorvastatin 10 \/ 20 \/ 40 mg, 30-180 tablets) from MedsBase with discreet packaging and worldwide shipping.<\/p>\n<h2 class=\"wp-block-heading\">Souvisej\u00edc\u00ed kardiologick\u00e1 a hypertenzn\u00ed l\u00e9\u010diva<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/cs\/aldactone\/\">Aldactone \u2014 Spironolakton (neselektivn\u00ed MR antagonista)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/amlode\/\">Amlode \u2014 Amlodipin (CCB)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/aten\/\">Aten \u2014 Atenolol (beta-blok\u00e1tor)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/cardace\/\">Cardace \u2014 Ramipril (ACE inhibitor)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/ecosprin\/\">Ecosprin \u2014 Aspirin 75\/150 mg<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/rosuline\/\">Rosuline \u2014 Rosuvastatin 5\/10 mg<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/high-blood-pressure-medication\/\"><strong>Prohl\u00e9dnout v\u0161echny l\u00e9ky na vysok\u00fd krevn\u00ed tlak<\/strong><\/a><\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:16px 20px;margin:24px 0;border-radius:4px;\"><strong>\u2695 L\u00e9ka\u0159sk\u00e9 upozorn\u011bn\u00ed.<\/strong> Tato str\u00e1nka slou\u017e\u00ed pouze pro informa\u010dn\u00ed \u00fa\u010dely a nenahrazuje l\u00e9ka\u0159skou p\u00e9\u010di kvalifikovan\u00e9ho zdravotnick\u00e9ho pracovn\u00edka. Hypertenze, srde\u010dn\u00ed selh\u00e1n\u00ed a arytmie vy\u017eaduj\u00ed diagn\u00f3zu, monitorov\u00e1n\u00ed a individu\u00e1ln\u00ed d\u00e1vkov\u00e1n\u00ed l\u00e9ka\u0159em \u2014 v\u017edy u\u017e\u00edvejte betablok\u00e1tory pod l\u00e9ka\u0159sk\u00fdm dohledem.<\/div>\n<h3 class=\"wp-block-heading\">Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n<p>Lipvas is supplied through a WHO-GMP certified manufacturer with full COA documentation. We ship worldwide in plain, discreet packaging, and every order is covered by our <a href=\"\/cs\/medsbase-re-shipment-assurance-policy\/\">Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/a>. V\u00e1\u0161 popis transakce p\u0159i platb\u011b kartou zobrazuje regulovan\u00e9ho zpracovatele plateb (regulovan\u00e9ho zpracovatele plateb kartou), nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Souvisej\u00edc\u00ed alternativy<\/h3>\n<p>Dal\u0161\u00ed produkty v <strong>Chronick\u00e1 onemocn\u011bn\u00ed<\/strong> kter\u00e9 z\u00e1kazn\u00edci tak\u00e9 prohl\u00ed\u017eej\u00ed:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/cs\/simvatic\/\">Simvatic<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/unibrom-eye-drops\/\">Unibrom Eye Drops<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/ciplactin\/\">Ciplactin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/glycoheal\/\">Glycoheal<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/flexabenz\/\">Flexabenz<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>Lipvas is Cipla&#8217;s atorvastatin 10\/20\/40 mg tablets \u2014 the most-used statin globally. Originally Parke-Davis\/Pfizer Lipitor (1996). Lipophilic, CYP3A4-cleared. Evidence: CARDS (primary prevention in diabetes), ASCOT-LLA (hypertensive dyslipidaemia), SPARCL (post-stroke), TNT (intensive secondary prevention). Dose range 10-80 mg, 40-80 mg = high-intensity. Reduces LDL-C by 50-55%. Grapefruit juice, CYP3A4 inhibitors substantially raise levels.<\/p>","protected":false},"featured_media":55613,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3356,3953],"product_tag":[3435,3954],"class_list":{"0":"post-55612","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-high-blood-pressure-medication","9":"product_cat-high-cholesterol-treatments","10":"product_tag-atorvastatin","11":"product_tag-lipvas","13":"first","14":"instock","15":"shipping-taxable","16":"purchasable","17":"product-type-variable","18":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product\/55612","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/comments?post=55612"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media\/55613"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media?parent=55612"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_brand?post=55612"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat?post=55612"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_tag?post=55612"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}